Pervasip Corp (OTCMKTS: PVSP) has been on the move northbound in recent weeks on a surge of trading volume and renewed interest from investors. PVSP has runner in its blood and saw a big move this time last year. The stock also has an established and significant shareholder base that will be back into PVSP heavily now that a clear upward momentum has been established. Currently PVSP trades just over 52 week lows and has a very significant gap to fill from where it was trading in April 2021. A big announcement is on the horizon; on the Company’s twitter account they posted: “Hello $PVSP shareholders: We are pleased to announce we are in the final phase of closing a strategic partnership that management believes will add an enormous amount of revenue to our bottom line. We look forward to announcing the details soon. Stay tuned!”
There are a lot of exciting things happening at PVSP; the Company’s 5% stake in KRTL Biotech seems to be paying off but it’s the Artizen acquisition that is bringing significant revenues to PVSP, revenues that put Pervasip above 99% of stocks on the OTCQB. Artizen is one of Washington’s original cannabis brands and is recognized as one of the most reputable leading consumer brands in the state. Earnings. Recognized as the 9th bestselling independent cannabis flower brand by MJ Business Magazine, Artizen further strengthened its market position by winning this year’s Dockside Cannabis Cup with its Dutchberry strain. Artizen subsidiary ZAM (Zen Asset Management) currently manages four licensed cultivation facilities and one licensed processing facility in Washington state. ZAM is also building out a next generation 24,000 square ft of cultivation and 9,000 square ft of processing capacity. PVSP has graduated to the revenue big leagues on the OTCQB reporting $17.1 million in revenue and about $530,000 in net income in fiscal 2021. For 2022 management is predicting big things; Artizen revenues are expected to incrase substantially by as much as 50% according to some. The Company is also expecting around $6 million in annual revenues from the Tacoma facility once its completed and another $5 million in annual revenues from the partnership with Full Spectrum Advisors.
Pervasip Corp (OTCMKTS: PVSP) is a developer of companies and technologies in high value emerging markets, owns Artizen Corporation and its subsidiary, Zen Asset Management LLC, a diversified asset management company founded to acquire, develop, and support companies and technologies in the cannabis industry. ZAM’s existing clients operate four licensed cannabis cultivation and one processing facility in Washington. Most of the biomass produced by these independent cultivators has been sold historically under the Artizen™ brand, including all-time top selling products in flower in Washington state. Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical grade resources and technologies as well as disciplines in the CBD, Psilocybin and certain psychedelics arena. The company’s scientists are leaders in cancer and neurology research, with over 80 years of experience in the research industry. KRTL Biotech Inc. has obtained the coveted approval of Korea’s Ministry of Food and Drug Safety (MFDS), formerly known as the Korea Food & Drug Administration (KFDA). The company has partnered with a multitude of universities and biotech companies to facilitate this venture.
Last year PVSP acquired Artizen Asset Management LLC (“AAM”) the parent of Zen Asset Management LLC (“ZAM”), a diversified asset management company that was founded to acquire, develop, and support companies and technologies in the cannabis industry. ZAM manages four licensed cultivation facilities and one licensed processing facility in Washington state under a series of management, leasing, licensing and other long-term agreements.
— Keith Kyak (@KeithKyak) April 27, 2022
To Find out the inside Scoop on PVSP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Hello $PVSP shareholders: We are pleased to announce we are in the final phase of closing a strategic partnership that management believes will add an enormous amount of revenue to our bottom line. We look forward to announcing the details soon. Stay tuned!
— Pervasip Corp. (@PervasipC) April 19, 2022
As one of Washington’s original cannabis brands, Artizen-branded products are the all-time fourth best-selling in Washington across all product categories, and the all-time third in flower, with five of the all-time top ten selling products in flower. Eighths of Artizen’s flagship Dutchberry™ flower are the all-time top selling flower product in Washington. Artizen’s commitment to quality and consistency has built a substantial following, fueling more than $69 million in wholesale sales to a distribution network with more than 200 retailers, corresponding to more than $200 million in retail value since inception in 2015. Go here for a full list of Artizen’s flower.
The Artizen brand is recognized as one of the most reputable leading consumer brands in Washington state, with tremendous consumer and retailer recognition. Management believes ZAM’s results in Washington are scalable with the right investment and management. Sales of Artizen-branded products have grown by more than 25% during the three years ended December 31, 2020, to more than $17 million in 2020. While that growth was historically driven by the continuing strong demand for Artizen-branded products, that demand significantly exceeds supplies. Additional growth is constrained by the availability of financing to invest in ZAM’s infrastructure and help its customers to increase utilization, sales, and earnings. Just last week ArtizenTM was announced as the winner of the esteemed Washington State 2022 Dockside Cannabis Cup. Recognized as the 9th bestselling independent cannabis flower brand by MJ Business Magazine, Artizen further strengthened its market position by winning this year’s Dockside Cannabis Cup with its Dutchberry strain.
Currently ZAM (Zen Asset Management) is building out a next generation cultivation facility in Tacoma, Washington consisting of 24,000 square feet of cultivation and 9,000 square feet of processing capacity, which ZAM will manage for three new ZAM customers. The new cultivation facility is projected to produce 500 pounds per month of high-quality cannabis flower and is scheduled for completion and launch by end of 2022. Pervasip management estimates the additional output to be initially valued at about $6 million in annualized revenues, with pre-tax operating income margins exceeding 10%.
In March Pervasip reported $17.1 million in revenue and about $530,000 in net income attributable to Pervasip’s shareholders for the year ended November 30, 2021 coming from its Artizen subsidiary. Wholesale sales increased by 330% for the year ended November 30, 2021, as compared to the year ended November 30, 2020, putting the Company on track to increase total sales to more than $30 million per year after construction of the Tacoma cultivation facility is completed. Pervasip Finanancial results will be further boosted by the Company’s strategic partnership with Full Spectrum Advisors (“FSA”), a cannabis cultivation group that has designed and operated over 7 million square feet of indoor canopy along with pioneering cutting-edge crop steering techniques. This partnership is expected to boost PVSP revenues by an additional $5 million annually over the next 24 months.
After recently announcing record Q1 financial results, CEO German Burtscher stated: “Our team has executed the first half of our restructuring plans flawlessly over the past few months. Improved gross margins, achieving positive EBITDA and quarter over quarter revenue growth even in the traditionally slowest quarter in our industry and compared to a pandemic high Q1 2021 is a testament to our strength, the direction of the Company and the power of the Artizen brand, “Our infrastructure is on track to achieve per square foot target objectives for harvest yields by Q4 this year, which will yield a 50% increase in output from all gardens. Together with the buildout of our new state of the art cultivation facility, this will continue to improve the company’s revenue and profitability.”
$PVSP Expecting 50% revenue growth from nation wide expansion🏆 #CannabisNews #cannabisindustry #cannabisstock #cbdproducts #CBD @MarketOverwatch @StockWeTrust #StocksToBuy @PervasipC https://t.co/v0uWKBlARn pic.twitter.com/AoxWypGGnn
— HELMER (@GoldenGlobeGGA) April 28, 2022
We have a Monster Pick Coming. Subscribe Right Now!
PVSP is an exciting story developing in small caps; the Company’s Artizen acquisition continues to pay off in spades achieving $17.1 million in revenue and about $530,000 in net income in fiscal 2021. For 2022 management is predicting big things; Artizen revenues are expected to incraese substantially by as much as 50% according to some sources; added to that will be an addition $10 million in new revenues coming from the new Tacome facility and the partnership with Full Spectrum Advisors. Management is excited about the Company’s pospects recently stating: “The Company started 2022 in a strong position according to management; We ended 2021 with numerous accomplishments, healthy financials, an amazing lineup of new opportunities, various strategic initiatives, and a companywide restructuring that we concluded over the past 3 months, after completing our acquisitions of Artizen Corporation and its subsidiary, Zen Asset Management LLC in September 2021. We have an amazing foundation to grow from in 2022, including close to $17 million in annual revenues, positive EBIDTA, one of the most established cannabis management companies in Washington state, and the intellectual property behind one of the top 10 national cannabis brands.” We will be updating on PVSP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PVSP.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in PVSP either long or short and we have not been compensated for this article.